The Market and Future Potential for Molecular Point of Care (mPOC), 2023
Description
The Market and Future Potential for Molecular Point of Care (mPOC), 2023
This report is an essential tool for understanding the size and growth opportunity in molecular POC. Molecular point of care (mPOC) has gone from novel trend to significant contributor to the market. The instruments sold by Abbott, BioMérieux, Cepheid and increasingly, a host of other companies, are a significant contributor to the IVD POC market. Knowing these markets is essential to knowing the opportunity in point of care testing and microbiology IVD.
Since 2013, Kalorama has been producing a dedicated report on systems and consumables. The Market and Future Potential for Molecular Point of Care (POC), 2023 is Kalorama’s latest. The report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.
Kalorama reports provide real-world analysis and model for relevant circumstances. As an example, analysts provide two different market perspectives. Near patient molecular testing using small instruments, and molecular point-of-care. Both markets are provided so the report can be useful for any business plans. As far as we know, Kalorama is the only market research resource providing this insight.
The data in The Market and Future Potential for Molecular Point of Care (POC), 2023 includes information on systems and competitor analysis, as well as data on the size and growth of the market:
Companies covered in this report, in profiles and/or product tables and market developments discussion include:
This report is an essential tool for understanding the size and growth opportunity in molecular POC. Molecular point of care (mPOC) has gone from novel trend to significant contributor to the market. The instruments sold by Abbott, BioMérieux, Cepheid and increasingly, a host of other companies, are a significant contributor to the IVD POC market. Knowing these markets is essential to knowing the opportunity in point of care testing and microbiology IVD.
Since 2013, Kalorama has been producing a dedicated report on systems and consumables. The Market and Future Potential for Molecular Point of Care (POC), 2023 is Kalorama’s latest. The report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.
Kalorama reports provide real-world analysis and model for relevant circumstances. As an example, analysts provide two different market perspectives. Near patient molecular testing using small instruments, and molecular point-of-care. Both markets are provided so the report can be useful for any business plans. As far as we know, Kalorama is the only market research resource providing this insight.
The data in The Market and Future Potential for Molecular Point of Care (POC), 2023 includes information on systems and competitor analysis, as well as data on the size and growth of the market:
- What are the mPOC market opportunities beyond COVID-19?
- What are the current systems on the market? Who’s winning?
- What’s the size of the Molecular Point of Care Market: 2022-2027
- Geographic Breakout of the Molecular Point of Care Market, 2021 (N. America, Europe, APAC, RoW)
- Segment Breakout of Molecular Point of Care Market, 2022 (Respiratory vs. Other)
- Respiratory Segment Breakout, 2022 (Flu, RSV, Strep, Other)
- Breakout of mPOC Respiratory, 2022 (%; Flu, Strep, RSV, Other)
- Near Patient Molecular IVD Market: 2022-2027
- Near Patient Molecular Market Share by Vendor, 2022
- Molecular Point of Care Market Share by Vendor, 2022
- Company Profiles
Companies covered in this report, in profiles and/or product tables and market developments discussion include:
- Abbott Laboratories
- Aidian Oy
- Akonni Biosystems
- Anitoa
- binx health, inc.
- Biocartis NV
- BioGX
- bioMérieux SA
- Cepheid
- Credo Bioscience
- Cue Health
- Curetis NV
- Curiosity Diagnostics (Bio-Rad)
- DiaSorin S.p.A
- Domus Diagnostics
- Fluxergy
- GenMark Diagnostics
- Genomadix
- Greiner Bio-One GmbH
- LEX Diagnostics
- Meridian Bioscience, Inc.
- Mesa Biotech, Inc.
- MicroGEM
- Minute Molecular
- Nanopath
- QIAGEN NV
- QuantuMDx Group
- Quidel Corporation
- Roche
- Rover Diagnostics
- Sekisui Diagnostics LLC
- T2 Biosystems
Table of Contents
137 Pages
- Molecular Point of Care Market, 2022-2026 ($M)
- Near Patient Molecular Systems Market: 2022-2027 ($M)
- Where is Molecular Point of Care in 2023?
- Molecular Point of Care Market Analysis
- Current Trends
- Usage of Molecular Point of Care
- Leading mPOC Platforms
- Trends
- Scope and Methodology
- COVID-19 and Molecular POC
- Recent Regulatory Developments
- Consortia, Funding, Prizes
- Deals
- Advantages and Disadvantages of Molecular Point of Care
- Justification: The Sensitivity/Specificity Argument
- New Systems and Menu Expansion
- Deals, Investment in mPOC Systems
- China as a POC Market
- Common Tests and Analytes in POC Diagnostics
- Component Technologies of Molecular Point-of-Care Diagnostics
- Applications and Potential Applications for Molecular Point-of-Care
- European Device Regulations Nearing
- Molecular Point of Care Market Analysis
- “Near Patient Molecular” Market
- Abbott Laboratories
- Aidian Oy
- Akonni Biosystems
- binx health, inc.
- Biocartis NV
- bioMérieux SA
- Cepheid (Danaher)
- Credo Diagnostics
- Cue Health
- Curetis NV (OpGen)
- DiaSorin S.p.A
- GenMark Diagnostics (Roche)
- Greiner Bio-One GmbH
- Lucira Health
- Meridian Bioscience, Inc.
- Mesa Biotech, Inc. (Thermo)
- QIAGEN NV
- QuantuMDx Group
- QuidelOrtho Corporation
- Roche
- Sekisui Diagnostics LLC
- T2 Biosystems
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
